Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by grosdavidon May 07, 2020 10:33am

77 Views

Post# 30997510

RE:Earliest they can what?

Am i stupid or analysis doesn't hold up? Like nothing points... can you conclude with what you are trying to say?

Is this another heartbreaking crying moment relatively to the PP?

Look around, it's like that everywhere no?

FDM.C had a PP at 0,05$ when the stock was trading around 0,06-0,07$, they closed the PP 2
months later for 756 000$ and the stock was trading at 0,49$ when it closed. Looks like the same clauses in the PP...

David

Bullboard Posts

Unique Battery Metals opportunity in Quebec